fda tirzepatide shortage resolved october 2 2024 Eli Lilly's is off the FDA's drug list: Here's what it means Lilly's Weight-Loss Drugs Zepbound, Mounjaro

GLP-1 receptor agonists are licensed in the UK for type 2 diabetes mellitus and specific weight management indications, not for cognitive impairment or dementia GLP-1 receptors are present in brain regions involved in memory and learning, prompting research into potential neuroprotective effects Ongoing clinical trials, including studies of semaglutide in Alzheimer's disease, are examining whether these medications benefit cognitive function Common adverse effects include gastrointestinal symptoms

Instead of backing down from the challenges over the past year, our team members have rolled up their sleeves, taken on new responsibilities and shown fearless leadership to continue the life-saving work we do every day

But now, new research is giving patients and physicians reason to feel hopeful

The most direct evidence comes from SURMOUNT-5 , a head-to-head randomized trial comparing the two medications in adults with obesity (without diabetes)

PDA is not specifically listed as a Category 2 substance

GLP-1 RAs and SGLT2i have different and synergistic effects in CKM syndrome